Biostatistics_Staburo_diabetesAnother publication with Staburo biostatistics support, this time in diabetes type 2.

Background: Studies of dipeptidyl peptidase (DPP)-4 inhibitors report heterogeneous effects on endothelial function in patients with type 2 diabetes (T2D). This study assessed the effects of the DPP-4 inhibitor linagliptin versus the sulphonylurea glimepiride and placebo on measures of macro- and microvascular endothelial function in patients with T2D who represented a primary cardiovascular disease prevention population.

The full publication can be found here:

Enjoy reading!

Feel free to reach out to us if you need support in your study!